ONEWORLD: BA & AA launch COVID-19 trials on TransAtlantic routes
American Airlines, British Airways and Oneworld have launched an optional COVID-19 medical-based testing trial on selected flights from the United States (US) to London Heathrow (LHR), in a combined effort to scientifically demonstrate how COVID-19 testing can reopen international travel and remove the need for passengers to quarantine on arrival.
Sean Doyle, Chief Executive of British Airways said: “We need the UK Government to introduce a system that allows travellers to take reliable, affordable tests before departure, so they are confident that fellow passengers are COVID-free. For people arriving from countries with high infection rates, a further test on arrival should then release them from quarantine.
“We are confident this approach would open routes, stimulate economies and get people travelling with confidence. The UK’s economic recovery depends on the swift reopening of its skies.”
The tests will be free to eligible passengers on American Airlines flight AA50 departing Dallas/ Fort Worth (DFW) to LHR; British Airways flight BA114 departing New York’s John F. Kennedy Airport (JFK) to LHR; and British Airways flight BA268 from Los Angeles (LAX) to LHR, beginning 25 November. The test will be expanded to American Airlines flight AA106 from JFK to LHR, with a launch date to be announced.
Eligible customers booked on flights that are part of the trial will be contacted by American Airlines and British Airways with instructions on how to volunteer. Each customer participating in the trial will take three tests in conjunction with the journey. If a customer tests positive, they should reschedule or cancel their travel.
The first test, to be taken 72 hours before departure from the US, is a convenient at-home RT-PCR test provided by LetsGetChecked. Customers will self-collect a nasal sample, under the supervision of medical professionals via a virtual visit.
After landing at LHR, participating customers will proceed to their second test at the airport. The LAMP test, provided by Collinson, involves the collection of a nasal sample by a medical professional. After the test is completed, a test kit for the third test will be provided to the customer. The test kit offers an at-home testing option, through the self-collection of a saliva sample which is taken three days after arrival in to the United Kingdom (UK).
The three-test approach aims to validate a customer’s negative status for COVID-19 throughout the travel journey and will provide insight into the most effective and practical testing interval. The third test is intended to further confirm the results of the first two tests, to demonstrate that one or two tests will be sufficient to allow travel to safely restart.
A task force comprising oneworld member airline representatives and independent medical experts are overseeing the implementation of the trial. American Airlines, British Airways and oneworld will closely monitor customer participation. The task force will share aggregated results with the US and UK Governments and other stakeholders to demonstrate the essential role that COVID-19 testing programmes can play in safely restarting travel.
Trade between the UK and US totals more than £200 billion (US$ 262 billion) a year, which airlines are critical to facilitating. Prior to the COVID-19 pandemic, together American Airlines and British Airways flew to more than 30 destinations in the US from London. Today, the carriers are flying a fraction of that figure. Previously, the carriers operated up to 111 flights a week from London to New York; now they operate 14* flights per week combined, between the two cities.
Based on current UK Government policies, international travellers arriving in the UK from the US are required to self-isolate for 14 days even if they have tested negative for COVID-19. The tests being used as part of the trial will not impact UK National Health Service testing capacity.
British Airways and American Airlines have worked with Heathrow on implementation of the trial in to Terminal 5, and as a result Heathrow is now exploring whether trials can be introduced on more routes between the airport and the US.